Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliapixant PK/Safety in Healthy Chinese Males
NCT04802343Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic cough comparing Eliapixant Arms with Placebo Arm (2 arms). Primary endpoints: Maximum observed drug concentration (Cmax) of BAY1817080 dose 1 and dose 2 at Day 1, Maximum observed drug concentration (Cmax) of BAY1817080 dose 3 at Day 1 and 4 more. Started Apr 2021; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT04802343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802343.